Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;13(5):3351-3356.
doi: 10.21037/qims-22-997. Epub 2023 Mar 24.

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description

Mingyue Tang  1 , Xinwei Li  1 , Yue Zhang  1 , Huiyuan Li  1 , Cancan Zhao  2 , Menglin Zhao  1 , Yanyan Wang  1   3 , Chenchen Jiang  4 , Fang Su  1
Affiliations

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description

Mingyue Tang et al. Quant Imaging Med Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-22-997/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Imaging and pathological examination of the patient. (A) The patient’s 3 chest CT scans showed old pulmonary tuberculosis lesions in the right lung; (B) patient’s lung primary lesions on Mar 22, 2021; (C) immunohistopathological analysis of the puncture biopsy of the left pulmonary lesions; (D) the patient’s lung infection and left pleural effusion on Apr 06, 2021. CK7, cytokeratin 7; TTF-1, thyroid transcription factor 1.
Figure 2
Figure 2
Imaging examination of the patient after treatment. (A) The patient was administered oral crizotinib, and there was no brain metastasis on reexamination after 5 months (Aug 31, 2021); (B) the patient was administered oral crizotinib, and the lung lesions were smaller on reexamination after 5 months (Sep 1, 2021); (C) the patient received oral crizotinib, and the lung lesions were smaller after 10 months (Feb 11, 2022).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer. J Thorac Dis 2013;5 Suppl 5:S463-78. - PMC - PubMed
    1. Tiwari D, Brodie SA, Brandes JC. Targeted therapy of non-small-cell lung carcinoma. Ther Adv Respir Dis 2012;6:41-56. 10.1177/1753465811404590 - DOI - PubMed
    1. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crinò L. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47. 10.1016/S1470-2045(12)70489-8 - DOI - PubMed
    1. Pasquini G, Giaccone G. C-MET inhibitors for advanced non-small cell lung cancer. Expert Opin Investig Drugs 2018;27:363-75. 10.1080/13543784.2018.1462336 - DOI - PubMed